March 21, 2026

Market Outlook and Forecast

Facioscapulohumeral Muscular Dystrophy (FSHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Facioscapulohumeral Muscular Dystrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

February 27, 2026

Market Outlook and Forecast

Inherited Retinal Disease (IRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Inherited Retinal Disease (IRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inherited Retinal Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

February 3, 2026

Market Outlook and Forecast

Peanut Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Peanut Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Peanut Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

December 24, 2025

Market Outlook and Forecast

Diabetic Peripheral Neuropathy (DPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Diabetic Peripheral Neuropathy (DPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

May 19, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Pemphigus Vulgaris – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Pemphigus Vulgaris Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

May 21, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Oral Mucositis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Oral Mucositis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

May 10, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Neuromyelitis Optica Spectrum Disorder (NMOSD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

May 8, 2026

Emerging Therapy, Unmet Needs and TPP Insights

Neurotrophic Keratitis (NK) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Thelansis’s “Neurotrophic Keratitis (NK) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

May 17, 2026

Market Outlook and Forecast

Global Rosacea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global Rosacea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rosacea treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

March 23, 2026

Market Outlook and Forecast

Hereditary Transthyretin Amyloidosis (hATTR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Thelansis’s “Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Transthyretin Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

May 9, 2026

Market Outlook and Forecast

Global Prurigo Nodularis (PN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global Prurigo Nodularis (PN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prurigo Nodularis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

May 13, 2026

Market Outlook and Forecast

Global Primary Hyperoxaluria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Thelansis’s “Global Primary Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

1 2 182